Drug
Agomelatine clinical trials
Also written Valdoxan and AGO178.
- studies test it
- 17
- open now
- 1
- in phase 3
- 8
- first study started
- 2006
Keep track of what changes. Save the agomelatine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 2006 | 3 |
| 2007 | 2 |
| 2010 | 3 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 3
- 8
- Phase 4
- 7
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 9
Novartis Pharmaceuticals (4) · Novartis (4) · Central South University (1) · Kaohsiung Kai-Suan Psychiatric Hospital (1) · Central Institute of Mental Health, Mannheim (1) · Xinyu Zhou (1) · Hannover Medical School (1) · Shanghai Mental Health Center (1)
Often tested with
Tested in the same studies.
Sertraline (2) · Aripiprazole (2) · Escitalopram (2) · Phenobarbital (1) · Phenytoin (1) · Carbamazepine (1) · Oxcarbazepine (1) · Valproic Acid (1)
Studies
Open first, then newest update. How each study uses agomelatine is read from its arms, and is right about nine times in ten.
Testing it · 17
- Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)Not yet recruitingPhase 4Xinyu ZhouNCT07011693Written as Agomelatine
- A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With AgomelatineCompletedPhase 4Central South UniversityNCT04589143Written as Agomelatine
- A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in SchizophreniaStatus unknownPhase 4Shanghai Mental Health CenterNCT05646264Written as Agomelatine
- Prophylactic Effects of Agomelatine for Poststroke DepressionStatus unknownPhase 4First Affiliated Hospital, Sun Yat-Sen UniversityNCT05426304Written as Agomelatine
- Pharmacokinetics of AGO178 in Participants With Liver ImpairmentCompletedPhase 1Novartis PharmaceuticalsNCT01531309Written as AGO178
- Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)CompletedPhase 3Novartis PharmaceuticalsNCT01110902Written as Agomelatine (AGO178C)
- Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)TerminatedPhase 3Novartis PharmaceuticalsNCT01156415Written as AGO178
- Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive DisorderCompletedPhase 3Novartis PharmaceuticalsNCT01110889Written as Agomelatine (AGO178C)
- Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive DisorderCompletedPhase 3NovartisNCT00411099Written as agomelatine
- Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive DisorderCompletedPhase 3NovartisNCT00411242Written as agomelatine
- A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)CompletedPhase 3NovartisNCT00463242Written as Agomelatine
- Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive DisorderCompletedPhase 3NovartisNCT00467402Written as agomelatine
- Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed PatientsCompletedPhase 4Kaohsiung Kai-Suan Psychiatric HospitalNCT04181567Written as agomelatine
- Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)CompletedPhase 4Central Institute of Mental Health, MannheimNCT01822418Written as agomelatine
- Pharmacovigilance in Gerontopsychiatric PatientsTerminatedPhase 3Hannover Medical SchoolNCT02374567Written as Agomelatine
- Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)Status unknownPhase 4Baker Heart and Diabetes InstituteNCT01483053Written as Agomelatine
- The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive DisorderWithdrawnNot applicableNational Taiwan University HospitalNCT00451490Written as Agomelatine
Given in every arm · 1 — agomelatine is usual care beside what is tested
As the comparator · 1 — what is tested is compared with agomelatine
Codes
What other systems call agomelatine · ClinicalTrials.gg INT003763
- MeSH (NLM) C084711agomelatineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 137R1N49ADAGOMELATINEConfirmed FDA, NLM, Wikidata
- Wikidata Q395229agomelatineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C72684AgomelatineOne source FDA
- DrugBank DB06594One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C084711 | agomelatine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 137R1N49AD | AGOMELATINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q395229 | agomelatine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C72684 | Agomelatine | One source FDA |
| DrugBank | DB06594 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.